

Press Release – May 09, 2023

## EG 427 Appoints Ralph Laufer As New Member To Board of Directors

- ***Biotech and pharmaceutical industry veteran, Ralph Laufer, Ph.D., joins the Board of Directors as an independent member.***
- ***EG 427 is adding complementary expertise among its Board directors to support its ambitions.***

**PARIS, May 09, 2023** -- EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions based on its unique non-replicative HSV-1 vector platform, announced today the appointment of Ralph Laufer to the Board of Directors.

*"We are thrilled to welcome Ralph Laufer as a new Board member of EG 427," said Philippe Chambon, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of EG 427. "Ralph's experience in drug discovery throughout the industry, including in the gene therapy sector, will be a great support to strengthen our expanding pipeline."*


Mr. Laufer has over 30 years of drug discovery and development experience in the pharmaceutical, biotech and gene therapy industry. Currently Chief Scientific Officer at Lysogene, a clinical stage AAV gene therapy company, he previously was Senior Vice President at Teva Pharmaceuticals, Scientific Director at Istituto di Ricerche di Biologia Molecolare (IRBM), and Head of Pharmacology at Merck Research Laboratories in Rome. He contributed to the discovery and development of numerous clinical drug candidates and several approved neurology, antiviral and anticancer medicines. Mr. Laufer obtained a PhD in Biochemistry from the Hebrew University of Jerusalem and carried out postdoctoral training at the Institut Pasteur, Paris.

*"EG 427 is establishing itself as a leader in the development of non-replicative HSV-1 vectors as a novel gene therapy platform." said Mr. Laufer. "EG 427's technology, which is grounded in innovative and proprietary scientific discoveries, offers unique advantages over existing approaches, with great potential to treat diseases with high unmet medical need. I am delighted to join the board of EG 427 and contribute to the growth of the company."*

### **About EG 427**

EG 427 has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. It delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. We take advantage of it to design new treatments of peripheral nervous system disorders and beyond.

Our lead asset, EG110A, targets the silencing of type-C sensory neurons. It is first being developed in urology indications. Our earlier stage products are focused on modifying the neurotransmission of other subsets of neurons. Furthermore, we are building the necessary manufacturing efficiency to bring genomic medicine to more prevalent, high medical need indications.



# EG 427

PINPOINT GENE THERAPY

**Press Release** – May 09, 2023

Our HQ and labs are located in Paris, France.

For more information:

🌐 check our website at [www.eg427.com](http://www.eg427.com)

follows us on **LinkedIn** at [www.linkedin.com/company/eg427/](https://www.linkedin.com/company/eg427/)

## **Contacts:**

### **Company**

Philippe Chambon, M.D., Ph.D.

EG 427 Founder and CEO

US: 415-533-9359

FR: +33 7 70 02 22 08

[philippe@eg427.com](mailto:philippe@eg427.com)

### **Media**

#### **US**

Selina Husain / Robert Flamm, Ph.D.

Burns McClellan, Inc.

[shusein@burnsmc.com](mailto:shusein@burnsmc.com)

[mailto:/ rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

#### **EU**

Sophie Baumont

Rose Piquante Consulting

[sophie.baumont@rosepiquante-](mailto:sophie.baumont@rosepiquante-consulting.com)

[consulting.com](http://consulting.com)

